n a rather unusual move, a Wall Street analyst has written an open letter to Gilead Sciences, imploring the drug maker’s executive team to pursue a “meaningful” acquisition before cash flow declines too precipitously.

The missive, which was written by Barclays Bank analyst Geoff Meacham, reflects ongoing investor frustration that the company has yet to pursue a deal to help compensate for declining sales of hepatitis C drugs and disappointing study results for newer medicines.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.